logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Olaparib monotherapy for BRCA-mutated platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer

< Back

Olaparib monotherapy for BRCA-mutated platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer

Drugs

Cancer and Palliative Care

October 2019


Olaparib is a medicinal product currently in development for the treatment of Breast Cancer Gene (BRCA)-mutated relapsed ovarian, fallopian tube or primary peritoneal cancer in patients who have received at least 2 prior platinum treatments and have progressed at least 6 months after their last platinum treatment. Ovarian cancer includes a group of tumours that arise from diverse types of tissue contained in the ovary and can often spread from the ovary to any surface within the abdominal cavity including the fallopian tubes and peritoneal cavity.
Olaparib is given by mouth (tablets) and belongs to a group of drugs called poly (ADP-ribose) polymerase (PARP) enzyme inhibitors which act by preventing DNA damage repair in cancer cells, promoting cell death. Using olaparib may improve outcomes and reduce side effects in patients with relapsed ovarian cancer who have received prior platinum therapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts